Ross La Motte Mohs
About Ross La Motte Mohs
Ross La Motte Mohs is a Senior Principal Scientist at Bristol Myers Squibb, specializing in translational medicine and hematology. He has over two decades of experience in both academic and industry research environments.
Company
Ross La Motte Mohs is currently working at Bristol Myers Squibb as a Senior Principal Scientist on the Heme - Translational Medicine Disease Team in the Greater New York City area. His previous positions at the company include Principal Scientist for the same team from 2019 to 2020.
Title
Ross La Motte Mohs holds the title of Senior Principal Scientist in the Heme - Translational Medicine Disease Team at Bristol Myers Squibb. In this capacity, he leverages his extensive background in translational medicine and hematology.
Education and Expertise
Ross La Motte Mohs completed his BA in Biology from the University of Virginia in 1993. He then earned a Ph.D. in Biochemistry & Molecular Biology, Immunology from the University of Illinois Chicago in 1999. He also achieved a PostDoc in Human Immunology/Stem Cell Biology from the University of Toronto, where he studied from 2000 to 2008. He has extensive experience in translational medicine, particularly in hematology, and has worked in both academic and industry research environments.
Background
Ross La Motte Mohs has over two decades of experience in research and development. He began his career as a Postdoctoral Fellow at Sunnybrook Research Institute, where he later became a Research Associate, working there for a total of nine years. He then transitioned to industry roles, including positions at Wellstat Therapeutics, MacroGenics, Inc., Celgene, and multiple roles at Bristol Myers Squibb. Throughout his career, he has focused on translational medicine and hematology.
Career in Translational Medicine
Ross La Motte Mohs has made significant contributions in the field of translational medicine. At MacroGenics, Inc., he worked on cell biology and immunology research for six years, ascending to the role of Scientist III. At Celgene, he was a Principal Investigator, focusing on translational development and diagnostics. Currently, at Bristol Myers Squibb, he continues to apply his expertise in translational medicine and hematology as a Senior Principal Scientist.